Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Cost utility of lateral-flow urine lipoarabinomannan for tuberculosis diagnosis in HIV-infected African adults
International Journal of Tuberculosis and Lung Disease, Volume 17, No. 4, Year 2013
Notification
URL copied to clipboard!
Description
SETTING: In-patient hospitals in South Africa and Uganda. OBJECTIVE: To evaluate the cost-effectiveness of a lateral-flow urine lipoarabinomannan (LAM) test when added to existing strategies for tuberculosis (TB) diagnosis in human immunodeficiency virus infected adults (CD4+ T-cell counts < 100 cells/μl) with symptoms of active TB. DESIGN: Decision-analytic cost-utility model, with the primary outcome being the incremental cost-effectiveness ratio, expressed in 2010 US dollars per disability-adjusted life year (DALY) averted from the perspective of a public sector TB control program. RESULTS AND CONCLUSION: For every 1000 patients tested, adding lateral-flow urine LAM generated 80 incremental appropriate anti-tuberculosis treatments and averted 224 DALYs. Estimated cost utility was USS353 per DALY averted (95% uncertainty range S192-S1161) in South Africa and S86 per DALY averted (95% uncertainty range S49-S239) in Uganda, reflecting the lower treatment costs in Uganda. Cost utility was most sensitive to assay specificity, cost of anti-tuberculosis treatment, life expectancy after TB cure and cohort TB prevalence, but did not rise above S1500 per DALY averted in South Africa under any one-way sensitivity analysis. The probability of acceptability was >99.8% at a per- DALY willingness-to-pay threshold equal to the per capita gross domestic product in South Africa (S7275) and Uganda (S509). © 2013 The Union.
Authors & Co-Authors
Sun, D.
United States, Baltimore
Johns Hopkins Bloomberg School of Public Health
Dorman, Susan E.
United States, Baltimore
Johns Hopkins School of Medicine
United States, Baltimore
Johns Hopkins University
United States, Baltimore
Tuberculosis Clinical Diagnostics Research Consortium
Shah, Maunank S.
United States, Baltimore
Johns Hopkins School of Medicine
United States, Baltimore
Johns Hopkins University
United States, Baltimore
Tuberculosis Clinical Diagnostics Research Consortium
Manabe, Yukari C.
United States, Baltimore
Johns Hopkins University
Uganda, Kampala
Infectious Diseases Institute
Moodley, Vineshree Mischka
South Africa, Cape Town
Faculty of Health Sciences
South Africa, Observatory
Groote Schuur Hospital
Nicol, Mark P.
South Africa, Cape Town
Faculty of Health Sciences
Dowdy, David W.
United States, Baltimore
Johns Hopkins Bloomberg School of Public Health
United States, Baltimore
Johns Hopkins University
United States, Baltimore
Tuberculosis Clinical Diagnostics Research Consortium
Statistics
Citations: 34
Authors: 7
Affiliations: 7
Identifiers
Doi:
10.5588/ijtld.12.0627
ISSN:
10273719
Research Areas
Disability
Health System And Policy
Infectious Diseases
Study Design
Cross Sectional Study
Cohort Study
Study Locations
South Africa
Uganda